Phase 2 N=41 Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
Gastric Cancer
Primary: Disease Control Rate — 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Phase 2 N=18 Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Phase 2 N=53 Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders
Phase 2 N=27 Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Gastric Adenocarcinoma · Esophagogastric Junction · Gastric Cancer
Primary: Overall Survival (OS) — 11.96 Months
Phase 2 N=52 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
Gastric Adenocarcinoma · Barrett Esophagus
Primary: Objective Response Rate (ORR) — 3.92 Participants (%)
Phase 2 N=34 Docetaxel and Epirubicin in Advanced Gastric Cancer
Stomach Neoplasms
Primary: Overall Survival — 13.4 month
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 3 N=521 Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
Primary: Relapse-free Survival — 50.0; 60.2 percentage of participants
N/A N=60 Perianastomotic Drain After Gastrectomy (DRAG)
Gastric Cancer
Primary: a) Number of Participants With High Pain Levels (Using the Visual Analog Scale) — 31; 3 Participants
Phase 2 N=54 RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
Stomach Neoplasm
Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants
Phase 2 N=19 Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
Gastrointestinal Cancer
Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months
Phase 2 N=30 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Gastric Cancer · Stomach Cancer
Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants
Phase 2 N=9 IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Clinical Stage IV Gastric Cancer AJCC v8 · Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage IVA Gastric Cancer AJCC v8
Primary: Progression-free Survival — 1.1 Months
Phase 2 N=40 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Gastric Adenocarcinoma · Gastro-esophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) — 5.257 months
Phase 2 N=17 A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
Recurrent Gastric Cancer · Stage IV Gastric Cancer
Primary: Response Rate — 0 percentage of patients responding
Phase 1 N=20 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · GastroEsophageal Cancer
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants
Phase 2 N=96 Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial
Gastric Cancer
Primary: Response Rate — 28.9; 26.1 percentage of participants
Phase 3 N=855 Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
Primary: Relapse-free Survival Rate — 67.0; 64.9 percentage of participants
Phase 2 N=254 Docetaxel and Oxaliplatin in Gastric Cancer
Stomach Neoplasms
Primary: Time to Progression — 4.50; 7.66; 5.55 Months
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 3 N=656 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
Advanced Gastric Cancer
Primary: Overall Survival (OS) — 5.39; 4.34 Months
Phase 2 N=74 Study of GSK1363089 in Metastatic Gastric Cancer
Neoplasms, Gastrointestinal Tract
Primary: Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 0; 0…
Phase 2 N=63 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants
Phase 2 N=51 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
Metastatic Esophageal Carcinoma · Metastatic Gastric Carcinoma · Metastatic Gastroesophageal Junction Adenocarcinoma
Primary: Dose Limiting Toxicity and Maximum Tolerated Dose of Olaparib (Phase I) — 0; 1 Participants
Phase 2 N=40 Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Gastric Cancer
Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants
Phase 2 N=85 Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · Gastroesophageal Adenocarcinoma · Distal Esophageal Adenocarcinoma
Primary: Number of Participants With Progression at the 3 Month Follow up Visit — 15; 7 participants
Phase 2 N=80 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
Phase 3 N=81 Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Gastrointestinal Stromal Tumors
Primary: Progression-free Survival — 1.8; 0.9 Months